Business Update
Targacept to receive $20 million payment from AstraZeneca to continue developing AZD3480
Published in Mental Health Business Week, January 27th, 2007
AstraZeneca's determination to continue development triggers a $20 million milestone payment to Targacept under the parties' collaboration agreement. The announcement follows the completion by AstraZeneca of previously announced studies of AZD3480 (TC-1734).
Alzheimer disease is an area of medical need in the developed and developing world. Schizophrenia is a chronic, severe and disabling form of psychosis that, in addition to symptoms such as delusions and hallucinations, is often...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week
More Articles from Mental Health Business Week
- Alzheimer Disease
Potential Alzheimer disease treatment discovered in Wales, U.K. - Attention Deficit Hyperactivity Disorder
New River Pharmaceuticals, Shire receive approvable letter for Vyvanse - Awards
Rudolf Moos earns 2006 Dan Anderson Research Award - Business Update
Clinical Data completes Vilazodone manufacturing technology transfer under license with Merck KGaA - Business Update
GEO Group contracts with Florida departments to manage 123 more mental health forensic beds - Drug Abuse
Decline in drug abuse hopeful but more research and education needed - More from this issue of Mental Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
